Quick Search 
Drugs of the Future
Register or sign in

Drugs Fut 2007, 32(9): 788
ISSN 0377-8282
Copyright 2007 Clarivate Analytics
CCC: 0377-8282
DOI: 10.1358/dof.2007.032.09.1138229
Revill, P., Serradell, N., Bolos, J., Rosa, E.
Telaprevir is an investigational oral hepatitis C virus (HCV) protease inhibitor in phase II evaluation in combination with pegylated interferon and ribavirin for the treatment of chronically infected patients with genotype 1 hepatitis C. Interim results from a phase II trial indicated that this drug has the potential to shorten the duration of treatment for some patients with genotype 1 HCV. Additional phase II trials involve the treatment of patients who have failed previous interferon-based treatment, as well as treatment in the absence of ribavirin.

Full Text: HTMLPDF 

© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy